Pinnacle Financial Partners (PNFP) Receives a Buy from Barclays
Elevate Your Investing Strategy:
Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
According to TipRanks, Shaw is a 3-star analyst with an average return of 1.1% and a 53.28% success rate. Shaw covers the Financial sector, focusing on stocks such as UMB Financial, Cadence Bank, and BankUnited.
In addition to Barclays, Pinnacle Financial Partners also received a Buy from Truist Financial's John McDonald CFA in a report issued on July 25. However, on July 26, TR | OpenAI – 4o downgraded Pinnacle Financial Partners (NASDAQ: PNFP) to a Hold.
The company has a one-year high of $131.91 and a one-year low of $81.57. Currently, Pinnacle Financial Partners has an average volume of 673.6K.
Based on the recent corporate insider activity of 56 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of PNFP in relation to earlier this year. Most recently, in May 2025, Robert A. Jr. Mccabe, the CHAIRMAN of PNFP sold 50,589.00 shares for a total of $5,326,515.81.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
28 minutes ago
- Yahoo
Amgen Stock Sinks As Market Eyes MariTide's Next Move
Amgen Inc. (NASDAQ:AMGN) shares are trading lower on Wednesday, despite the company reporting second-quarter results that surpassed analyst expectations after markets closed on Tuesday. The US drug maker reported adjusted earnings of $6.02 per share, up 21% year over year, beating the consensus of $5.24. Amgen reported quarterly sales of $9.18 billion, up 9%, beating the Wall Street estimate of $8.87 sales grew 9%, driven by 13% volume growth, partially offset by 3% lower net selling price. Fifteen products delivered at least double-digit sales growth in the second quarter. Outlook Following the strong quarterly performance, Amgen raised fiscal year 2025 adjusted earnings guidance from $20.00-$21.20 per share to $20.20-$21.30 versus the consensus of $20.89. The company raised sales outlook from $34.30 billion-$35.70 billion to $35 billion-$36 billion versus the consensus of $35.29 billion. MariTide in Focus Despite the positive financial results, investor focus remains squarely on the company's experimental weight-loss drug, MariTide. A William Blair analyst noted that investors are 'hyper-focused' on the drug's progress. Part 2 of the Phase 2 chronic weight management study is ongoing in obese patients, with or without type 2 diabetes. Data readout is anticipated in the fourth quarter of 2025. View more earnings on AMGN A Phase 2 study investigating MariTide for type 2 diabetes is ongoing in adults with and without obesity. Data readout is anticipated in the fourth quarter of 2025. Analyst Matt Phipps of William Blair said, 'Given the trial is solely focused on the maintenance setting, we do not believe it will address the key question of tolerability that investors continue to debate.' Analyst Phipps says Amgen shares are up 15% year-to-date, although it remains volatile as investors debate clinical updates with MariTide given the significant market opportunity and competitive landscape. 'We believe Amgen has had meaningful clinical and commercial success with assets including Repatha, Evenity, Blincyto, Tezspire, Imdelltra, and Uplizna that support continued upside on top of the potentially differentiated profile of MariTide, and therefore reiterate our Outperform rating.' Amgen has some near-term headwinds from legacy products, including the recent launch of a biosimilar to Prolia and Xgeva at the end of May 2025 (recent settlement with Sandoz), and the difficulties in gaining more market share with the biosimilar franchises, but the analyst believes clinical catalysts over the next 6 to 12 months will provide meaningful reasons for investor excitement about the long-term growth prospects of the company. Check out . Price Action: AMGN stock is trading lower by 5.10% to $284.97 at last check Wednesday. Read Next:Photo by JHVEPhoto via Shutterstock Latest Ratings for AMGN Date Firm Action From To Feb 2022 Morgan Stanley Maintains Equal-Weight Feb 2022 Wells Fargo Maintains Equal-Weight Feb 2022 Barclays Maintains Equal-Weight View More Analyst Ratings for AMGN View the Latest Analyst Ratings Up Next: Transform your trading with Benzinga Edge's one-of-a-kind market trade ideas and tools. Click now to access unique insights that can set you ahead in today's competitive market. Get the latest stock analysis from Benzinga? AMGEN (AMGN): Free Stock Analysis Report This article Amgen Stock Sinks As Market Eyes MariTide's Next Move originally appeared on © 2025 Benzinga does not provide investment advice. All rights reserved. Sign in to access your portfolio
Business Wire
29 minutes ago
- Business Wire
Northern Trust Leaders to Participate in Barclays Global Financial Services Conference on September 9 th
CHICAGO--(BUSINESS WIRE)--Northern Trust Corporation announced today that Chief Financial Officer David Fox and Chief Operating Officer Peter Cherecwich will participate in the Barclays Global Financial Services Conference in New York City on Tuesday, September 9, 2025, at 4:15 p.m. (ET). A live webcast of the event may be accessed via Northern Trust's website ( in the investor relations section. A replay will be available for approximately four weeks after the session date. About Northern Trust Northern Trust Corporation (Nasdaq: NTRS) is a leading provider of wealth management, asset servicing, asset management and banking to corporations, institutions, affluent families and individuals. Founded in Chicago in 1889, Northern Trust has a global presence with offices in 24 U.S. states and Washington, D.C., and across 22 locations in Canada, Europe, the Middle East and the Asia-Pacific region. As of June 30, 2025, Northern Trust had assets under custody/administration of US$18.1 trillion, and assets under management of US$1.7 trillion. For more than 135 years, Northern Trust has earned distinction as an industry leader for exceptional service, financial expertise, integrity and innovation. Visit us on Follow us on Instagram @northerntrustcompany or Northern Trust on LinkedIn. Northern Trust Corporation, Head Office: 50 South La Salle Street, Chicago, Illinois 60603 U.S.A., incorporated with limited liability in the U.S. Global legal and regulatory information can be found at
Yahoo
an hour ago
- Yahoo
Tesla Says Retaining Elon Musk Is 'More Important Than Ever Before' As Company Kicks Off $29 Billion Compensation Process For CEO (UPDATED)
Benzinga and Yahoo Finance LLC may earn commission or revenue on some items through the links below. Editor's Note: This story has been revised to include new information. Tesla Inc. (NASDAQ:TSLA) has begun the process to award CEO Elon Musk with the compensation award amid uncertainty over the previous $56 billion pay package. Check out the current price of TSLA stock here. Elon Musk To Get 96 Million Tesla Shares As Compensation Taking to the social media platform X on Monday, Tesla shared a letter addressed to the shareholders of the company, announcing that it will begin the process to compensate Musk. The new pay package is worth around $29 billion. "Today we announce an important first step in compensating Elon Musk for his extraordinary work at Tesla," the company said in the statement on X, highlighting that Musk hasn't received "meaningful compensation in eight years" since 2017. Trending: Be part of the breakthrough that could replace plastic as we know it— No "Double Dip" For Musk The company also said it was "more important than ever before" to keep Musk as CEO, as Tesla is at 'a critical inflection point that has the potential to create continued extraordinary value," for the shareholders. The statement, issued by Board members Robyn Denholm and Kathleen Wilson-Thompson, stipulates that Musk would receive over 96 million shares in Tesla, each of which trades at just over $300, after anti-trust approval, but says that the shares have a holding period of five years unless Musk has to "cover tax payments or the purchase price." However, if the Delaware court reinstates Musk's $56 billion pay package, he must forfeit the current compensation. "To put it simply, there cannot be any 'double dip,'' the statement said. Musk Fears Losing Control Over Tesla Amid Dwindling Sales The announcement follows Musk expressing fears of losing control over Tesla, as the billionaire had denied any personal loans tied to his shares in the EV giant. "It is worrying in that I don't want to build millions of robots and then be potentially ousted by activists," Musk said. The comments come at a difficult time for the company, with sales figures dwindling in multiple markets throughout the world. Tesla's sales in Denmark, Sweden and France declined for the seventh consecutive month. Delaware Court Ruling And Musk's $56 Billion Pay Package The letter also comes in as a Delaware court in 2024 had overruled Musk's $56 billion pay package, which was approved by the members of Tesla's Board. Elsewhere, Tesla's board is set to hold its annual shareholder meeting in November, with experts like Wedbush Securities analyst Dan Ives saying Musk's pay package would be in focus. Tesla scores well on Momentum and Quality, while offering satisfactory Growth, but poor Value. For more such insights, sign up for Benzinga Edge Stock Rankings today! Read Next: $100k+ in investable assets? Match with a fiduciary advisor for free to learn how you can maximize your retirement and save on taxes – no cost, no obligation. Arrived Home's Private Credit Fund's has historically paid an annualized dividend yield of 8.1%*, which provides access to a pool of short-term loans backed by residential real estate with just a $100 minimum. Image via Shutterstock This article Tesla Says Retaining Elon Musk Is 'More Important Than Ever Before' As Company Kicks Off $29 Billion Compensation Process For CEO (UPDATED) originally appeared on
